MRT-9643 / Monte Rosa Therap - LARVOL DELTA

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer (GlobeNewswire) - "Monte Rosa Therapeutics, Inc...announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader to treat HR-positive/HER2-negative breast cancer at the 2024 San Antonio Breast Cancer Symposium, held December 10-13 in San Antonio, Texas....'We look forward to advancing our CDK2 MGD program towards a development candidate nomination in H1 2025'....In cellular assays, MRT-9643 induced deep CDK2 degradation, resulting in CDK2-dependent cancer cell growth inhibition....MRT-9643 demonstrated superior selectivity as compared to several clinical-stage small molecule CDK2 inhibitors evaluated. The combination of MRT-9643 and ribociclib, an FDA-approved CDK4/6 inhibitor, delayed resistance to CDK4/6 inhibition both in vitro and in vivo."

Preclinical • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 (GlobeNewswire) - "The Company expects to nominate a development candidate for the CDK2 preclinical program in 2024."

Preclinical • Oncology

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) - "The Company now expects to release the recommended Phase 2 dose for the MRT-2359 Phase 1/2 study in Q2 2024. On track for planned IND submission for MRT-6160 in the first half of 2024. The Company expects to nominate a development candidate for its NEK7 preclinical program in Q1 2024. The Company expects to nominate a development candidate for its CDK2 preclinical program in 2024."

IND • P1/2 data • Pipeline update • Immunology • Oncology • Solid Tumor